Glucagon-like peptide-1

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.

At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.

Reverse-phase silica media for GLP‑1 and other peptides; available in C8 and C18 chemistries for high-resolution separations and integration with AmberChrom polymeric resins from development to manufacturing.

Approvals include Rasonque for metastatic pancreatic cancer, Foundayo oral GLP‑1 for weight and type 2 diabetes, Yuviwel for achondroplasia, two biosimilars and temozolomide for gliomas.

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.